Lv61
2610 积分 2021-09-04 加入
工作太多了！
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
2天前
已关闭
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
6天前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
7天前
已完结
PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer
29天前
已完结
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update
1个月前
已完结
Efficacy and safety of taletrectinib for treatment of ROS1 positive non-small cell lung cancer: A systematic review
1个月前
已完结
Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies
1个月前
已完结
Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers
2个月前
已关闭
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
2个月前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
